指南与共识MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

美国血液学会2026年成人骨髓纤维化管理指南

American Society of Hematology 2026 Guidelines for the Management of Myelofibrosis in Adults.
指南 / 共识 · Blood Adv · 2026-10-14

ASH组建多学科指南小组,基于截至2025年1月31日的系统证据评价,采用GRADE方法制定成人骨髓纤维化管理指南。小组就预后检测、干扰素与JAK抑制剂指征、贫血管理、移植时机、抗血小板治疗和铁螯合达成10条推荐。关键推荐包括扩展分子遗传学检测、对有症状低危患者使用JAK抑制剂、骨髓纤维化贫血及JAK抑制剂诱导贫血的治疗策略和移植转诊时机与术前优化。

要点

  • 建议对骨髓纤维化患者进行扩展分子遗传学检测以完善预后评估。
  • 对有症状的低危骨髓纤维化患者,建议使用JAK抑制剂治疗。
  • 需关注骨髓纤维化相关贫血及JAK抑制剂诱导贫血的治疗策略。

核心结论

  • 指南就预后检测、干扰素与JAK抑制剂指征、贫血管理、移植时机、抗血小板治疗和铁螯合达成10条推荐。

研究设计与样本

  • ASH组建多学科指南小组,包括骨髓纤维化及造血干细胞移植专家、2名患者代表,并平衡利益冲突。
  • Mayo Clinic循证实践中心支持指南制定,更新或执行系统证据评价(截至2025年1月31日)。
  • 小组采用GRADE方法(包括GRADE Evidence-to-Decision框架)评估证据并形成推荐,推荐草案经过公开评论。

主要发现

  • 小组就预后检测、干扰素和JAK抑制剂治疗指征、骨髓纤维化相关贫血管理、移植时机、抗血小板治疗和铁螯合达成10条推荐。

关键数值与推荐

  • 推荐对有症状的低危骨髓纤维化患者使用JAK抑制剂。
  • 建议进行扩展分子遗传学检测。
  • 推荐涉及骨髓纤维化贫血及JAK抑制剂诱导贫血的治疗策略。
  • 推荐涉及造血干细胞移植的转诊时机及移植前优化。

临床怎么用

  • 临床应依据症状负荷、预后及治疗获益风险选择个体化方案。
  • 对有症状低危患者可考虑JAK抑制剂治疗。
  • 应关注骨髓纤维化贫血及JAK抑制剂诱导贫血的管理。
  • 造血干细胞移植需把握转诊时机并做好移植前优化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myelofibrosis (MF) is a myeloid bone marrow malignancy with a progressive clinical course marked by disease-related symptoms, splenomegaly, cytopenias, thrombosis/hemorrhage, and a risk for blast phase transformation. Treatment recommendations are based on the burden of symptoms, prognosis of the disease, and benefits/risks of each treatment modality. METHODS: ASH formed a multidisciplinary guideline panel that included specialists in myelofibrosis and hematopoietic cell transplantation, as well 2 patient representatives and was balanced to minimize potential bias from conflicts of interest. The Mayo Clinic Evidence-based Practice Center supported the guideline development process, including updating or performing systematic evidence reviews (up to January 31, 2025). The panel prioritized clinical questions and outcomes according to their importance for patients and clinicians. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 10 recommendations regarding prognostic testing, indications for interferon and JAK inhibitor therapy, management of MF-associated anemia, timing of transplantation, anti-platelet therapy, and iron chelation. CONCLUSIONS: Key recommendations of these guidelines include suggestions for extended molecular genetic testing; use of JAK-inhibition in symptomatic, lower risk MF patients; therapeutic strategies for patients with MF-anemia and JAK-inhibitor induced anemia; and considerations regarding hematopoietic cell transplantation including timing of referral and optimization prior to the procedure. Key future research agendas were identified for all recommendations.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Stein BL, Abdallah MM, Abel GA, et al. American Society of Hematology 2026 Guidelines for the Management of Myelofibrosis in Adults. Blood Adv. 2026. PMID: 42873117. doi:10.1182/bloodadvances.2026021650

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。